XOMA Corp (NASDAQ:XOMA) – Wedbush issued their Q1 2021 earnings per share (EPS) estimates for shares of XOMA in a research note issued on Monday, March 23rd. Wedbush analyst L. Moussatos anticipates that the biotechnology company will post earnings of ($0.10) per share for the quarter. Wedbush has a “Buy” rating and a $29.00 price objective on the stock. Wedbush also issued estimates for XOMA’s Q2 2021 earnings at ($0.12) EPS, Q3 2021 earnings at ($0.11) EPS and Q4 2021 earnings at ($0.12) EPS.
XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $0.42 million for the quarter, compared to analysts’ expectations of $3.24 million. XOMA had a negative net margin of 18.01% and a negative return on equity of 11.53%.
Several other equities research analysts have also recently weighed in on the company. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a report on Saturday, February 15th. Zacks Investment Research restated a “hold” rating on shares of XOMA in a report on Saturday, March 14th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of XOMA in a report on Monday, March 9th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. XOMA presently has a consensus rating of “Buy” and an average target price of $28.67.
Shares of XOMA stock opened at $19.50 on Thursday. The stock has a market capitalization of $169.76 million, a PE ratio of -35.45 and a beta of 1.12. XOMA has a 1-year low of $11.58 and a 1-year high of $28.85. The business has a 50-day moving average of $22.72 and a 200 day moving average of $22.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.76 and a quick ratio of 6.76.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. BVF Inc. IL raised its position in XOMA by 47.1% during the 4th quarter. BVF Inc. IL now owns 2,642,405 shares of the biotechnology company’s stock valued at $72,138,000 after purchasing an additional 845,463 shares during the last quarter. Renaissance Technologies LLC bought a new position in XOMA during the 4th quarter valued at approximately $2,450,000. Credit Suisse AG bought a new position in XOMA during the 4th quarter valued at approximately $1,472,000. Marshall Wace LLP bought a new position in XOMA during the 4th quarter valued at approximately $1,229,000. Finally, EAM Investors LLC bought a new position in XOMA during the 4th quarter valued at approximately $1,052,000. 46.67% of the stock is owned by institutional investors and hedge funds.
In other XOMA news, major shareholder Bvf Partners L. P/Il purchased 100,000 shares of the stock in a transaction on Friday, March 13th. The stock was acquired at an average price of $18.34 per share, with a total value of $1,834,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Value Fund L. P. Biotechnology purchased 118,277 shares of the stock in a transaction on Tuesday, March 17th. The shares were acquired at an average cost of $16.90 per share, with a total value of $1,998,881.30. The disclosure for this purchase can be found here. Insiders have purchased a total of 220,277 shares of company stock valued at $3,866,681 over the last 90 days. 9.89% of the stock is currently owned by company insiders.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
See Also: Equity Income
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.